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Background and aim: Systemic inflammation is related to the progression of complica-
tions associated with diabetes. This study aimed to investigate the association between
general and abdominal obesity and inflammation in patients with type-2 diabetes with or
without glycemic control.
Methods: A total of 198 men (n=73) and women (n=125) diagnosed with type 2 diabetes
participated in this study. General obesity markers, body mass index (BMI), and abdominal fat
were assessed. Circulating concentrations of glycated hemoglobin (HbA1C), C-reactive protein
(CRP), and serum interleukin-6 (IL-6) were determined. Poor glycemic control and good glycemic
control were defined as having fasting HbA1C concentrations ≥7% and <7%, respectively.
Multivariate adjusted analysis of covariance was used to determine the relation between BMI
and abdominal fat and markers of inflammation in patients with good and poor glycemic control.
Results: Patients in <7% HbA1C category, those with high abdominal fat had ≈262% higher
CRP and ≈30.6% higher IL-6 compared to those with low abdominal fat (p˂0.05). Patients in
≥7% HbA1C category, those with high abdominal fat had ≈41.4% higher CRP and ≈33.9%
higher IL-6 compared to those with low abdominal fat (p˂0.05). Abdominal fat was directly
related to CRP (p˂0.023) and IL-6 (p˂0.002) concentrations in both groups of type-2
diabetic patients with <7% and ≥7% HbA1C. In patients with ≥7% HbA1C, BMI was
directly related to CRP (p˂0.02) and IL-6 (p˂0.047). Whereas in patients with <7%
HbA1C, BMI was not associated with CRP or IL-6 concentrations.
Conclusion: High level of abdominal fat is associated with systemic inflammation in type-2
diabetes regardless of glycemic control. Abdominal fat is a better predictor (determinant) of
inflammation than BMI in patients with type-2 diabetes with or without glycemic control.
Keywords: BMI, C-reactive protein, diabetes, IL-6, inflammation, obesity
Introduction
Type 2 diabetes mellitus (T2D) is a progressive, common disease characterized by
hyperglycemia resulting from defects in insulin action. T2D is considered one of the
costliest chronic diseases with strong association with many chronic diseases, such as
renal failure, atherosclerotic vascular disease, hypertension, and dyslipidemia.1–3
Systemic inflammation is the continuous phenomenon of the immune response
which can promote tissue damage.4 Chronic systemic inflammation arises due to the
persistence of a pro-inflammatory substance. This environment could be the result of
a pro-inflammatory stimulus or inadequate determination of the inflammatory
response.5,6 The relationship between inflammation and diabetes is complicated.
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Intermediary role of inflammation has been established in
many studies in the occurrence of T2D and its long-term
complications.7 Several connections have been proposed.
One suggests that inflammation plays a vital role in diabetes
pathogenesis through the induction of β cell apoptosis in
T2D by the activity of reactive oxygen species and inflam-
matory cytokines.8–11 A large body of research supports the
finding that systemic inflammation is associated with insulin
resistance.12–14 Experiments conducted on animals and stu-
dies in humans displayed a strong association between low-
grade inflammation and increased insulin resistance,15,16
leading to elevated glucose concentrations.
Diabetes complications such as cardiovascular diseases,
are often characterized by diabetes-induced systemic
inflammation.17,18 Elevated inflammation characterized by
increased concentration of IL-6 was significantly related to
progression of microvascular complications of diabetes.19
Elevated inflammatory markers such as CRP and IL-6 are
inversely related to nerve conduction velocities and directly
related to peripheral neuropathy, even in non-diabetic
persons.20 Despite the continuous work dedicated to gaining
an in-depth understanding of the relation between inflam-
mation and diabetes pathogenesis and progression, the role
of glycemic control in inflammation is not clear in
Jordanian population. Therefore, this study aimed to inves-
tigate the association between general and abdominal obe-
sity and inflammatory biomarkers in patients with or
without glycemic control.
Methods
This study was conducted in accordance with the
Declaration of Helsinki. The protocol of this study was
approved by the Institutional Review Board at Jordan
University of Science and Technology (JUST). Patients
were recruited from the outpatient endocrinology unit at
King Abdullah University Hospital, JUST Health Center,
and private endocrinology clinics in the north of Jordan.
Initial screening included 1500 patients diagnosed with
T2D. Due to the multiple co-variation nature of the relation-
ship of interest, about 87% of the initially screened patients
were excluded from the study. The final study sample com-
prised 198 patients (73 male and 125 female) diagnosed with
type 2 diabetes. Patients were excluded if they met one of the
following criteria: 1) diagnosed with T2D for less than one
year; 2) also diagnosedwith either rheumatoid arthritis, cancer,
diabetic foot, kidney diseases, or any chronic or acute inflam-
matory disease; 3) had a recent major or minor surgery; 4) on
non-steroidal anti-inflammatory drugs for less than two weeks
prior to the blood sample collection; 5) women on oral contra-
ceptives; and 6) women who were pregnant. All 198 patients
completed the study. All subjects signed informed consent
after all study procedures were explained.
Blood Specimen Collection And Analysis
A 10-mL blood sample was collected by venipuncture by a
registered nurse. For measurement of HbA1c, blood sam-
ples were collected in ethylenediaminetetraacetic acid tubes.
Then HbA1C was measured in whole blood using the
immune-inhibition test for the quantitative determination
of glycosylated hemoglobin (Beckman Coulter AU analy-
zers). For the measurement of CRP and IL-6, blood was
collected in Z-Clot activator tubes. Blood was allowed to
clot before centrifugation for 15 mins at 1000×g. Aliquots
of serum were stored at ≤ −22°C in sterile small tubes prior
to biochemical assay. CRP and IL-6 concentrations were
analyzed within a month after collection of blood. The
immuno-turbidimetric test was used to determine CRP
levels (Beckman Coulter AU analyzers). IL-6 was measured
using a human immunoassay kit from R&D SYSTEMS
through sandwich-type enzyme-linked immunosorbent
assay. An Absorbance Microplate Reader was used to mea-
sure the optical density of IL-6 (BioTek ELx800).
Anthropometrics And Body Composition
Weight and height were measured following World Health
Organization (WHO) procedures.21 Body weight was mea-
sured with the individuals wearing no shoes and light cloth-
ing. Height was measured using a measuring rod (Seca,
Germany). Body mass index (BMI) was calculated using
the ratio of weight (kilograms) to the square of height
(meters) (kg/m2). The WHO BMI cutoff points were used
to classify patients into different body weight categories.21
Patients’ abdominal fat percentage was determined
using the bioelectrical impedance technique (TANITA,
BC-418). The Segmental Body Composition Analyzer
(TANITA, BC-418) used in this study was previously
validated against hydro-densitometry in the assessment of
body composition in healthy young adults.22 The cutoff
points for abdominal fat percentage were gender-specific,
based on which patients were classified into low, average,
and high abdominal fat.23
Statistical Analysis
Statistical Package for Social Sciences (SPSS, version 19,
Chicago: SPSS Inc.) software was used in data analysis.
Characteristics of subjects’ variables were described using
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frequency distribution for categorical variables and mean
and standard deviation for continuous variables. Patients
were classified as having good glycemic control if they
had <7% HbA1C. If a patient had ≥7% HbA1C, that
patient was categorized as having poor glycemic control.
Multivariate-adjusted analysis of variance (MANOVA)
was used to examine the differences in mean serum levels
of CRP and IL-6 in patients with good and poor glycemic
control. Analysis was adjusted for age, gender, use of
lipid-lowering drugs, and diabetes duration. Least signifi-
cant difference post-hoc MANOVA was conducted to
determine which two means differ within the BMI and
abdominal fat categories. A p-value of <0.05 was consid-
ered the cutoff level for statistical significance.
Results
Table 1 shows characteristics of the study participants. The
majority of the participants were >50 years old. More than
2/3 of the sample (75.8%) were nonsmokers. The glycemic
control was poor for 66.2% of the patients. Lipid lowering
drugs were used by 19.7% of the participants. 7.1% of the
participants had a normal BMI. 27.8% were overweight,
and 65.1% were obese. Only 7.5% of the participants had
abdominal fat at low level, while 68.7% presented with
normal level, and 20.2% had high fat level. We performed
an additional analysis on gender and age differences
regarding inflation. We found no significant difference
between men and women (except CRP in poor glycemic
group) and between older and younger persons regarding
CRP and IL-6 concentrations in both glycemic groups
(data not shown). However, the analysis was adjusted for
these variables.
Table 2 shows the association between BMI and abdom-
inal fat and inflammatory biomarkers in patients with con-
trolled glycemia. Patients with good glycemic control (<7%
HbA1C) with high abdominal fat had ~262% higher CRP
and ~30.6% higher IL-6 compared to those with low abdom-
inal fat (p˂0.05). Among patients with good glycemic con-
trol, no significant association was found between BMI and
inflammatory markers (CRP or IL-6).
Table 3 shows the relation between BMI and abdom-
inal fat and inflammatory biomarkers in patients with
uncontrolled glycemia. Patients with poor glycemic con-
trol (≥7% HbA1C), with high abdominal fat had ≈41.4%
higher CRP and ≈33.9% higher IL-6 compared to those
with low abdominal fat (p˂0.05). Patients with poor gly-
cemic control with obesity grade III had ≈206% higher
CRP and ≈50.2% higher IL-6 compared to those with
normal BMI.
Discussion
An interesting finding of the current study is that the inflam-
matory markers studied (CRP, IL-6) were higher among
patients with higher BMI; however, this finding was observed
only among patients with poor glycemic control. In other
words, obese patients with controlled diabetes (HbA1c ˂7%)
had less systemic inflammation despite having diabetes and
obesity. This might be explained by the impact of a consistent
state of hyperglycemia (HbA1c ˃7%), which may lead to up-
regulation of acute phase inflammatory markers such as amy-
loid A3 (SAA3) and pro-inflammatory cytokines such as IL-6,
by adipose tissue under the stimulation of high blood
glucose.24 Elevation of IL-6 may in turn stimulate the produc-
tion of CRP by the hepatocytes.25,26 Ray et al stated that
elevated levels of glucose resulting from obesity can create
stress in pancreatic islets, adipose tissue, liver, and muscle.27
Table 1 Participants’ Characteristics – Glycemic Control (N=198)
Variable Glycemic Controla
Good (n=67) Poor (n=131)
Gender n (%) n (%)
Men (n=73) 25 (34.2) 48 (65.8)
Women (n=125) 42 (33.6) 83 (66.4)
Age (years)
30–49 (n=48) 21 (43.8) 27 (56.2)
50–80 (n=150) 46 (30.7) 104 (69.3)
Diabetes duration (years)
≤5 (n=94) 47 (50) 47 (50)
6–12 (n=61) 12 (19.7) 49 (80.3)
13–19 (n=24) 6 (25) 18 (75)
>20 (n=17) 2 (11.8) 15 (88.2)
Not reported (n=2) 0 (0) 2 (100)
Body mass indexb
Normal weight (n=14) 6 (42.9) 8 (57.1)
Overweight (n=55) 25 (45.5) 30 (54.5)
Obese (n=129) 36 (27.9) 93 (72.1)
Lipid-lowering drugs
Yes (n=39) 15 (37.5) 25 (62.5)
No (n=159) 52 (32.9) 106 (67.1)
Smoking status
Yes (n=48) 15 (31.3) 33 (68.8)
No (n=150) 52 (34.7) 98 (65.3)
Notes: aGood glycemic control is defined as having HbA1C <7%, while poor glycemic
control is having HbA1C ≥7%. bNormal weight, BMI: 18.6 to <24.9 kg/m2; overweight:
BMI: 25 to 29.9 kg/m2; obese grade I: BMI: 30 to 34.9 kg/m2; obese grade II: BMI: 35 to
39.9 kg/m2; and obese grade III: BMI: ≥40 kg/m2.
Dovepress Bawadi et al
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Consequently, there is a surge in local production and release of
cytokines and chemokines, such as IL-6 and TNF-α. These
changes enhance further production and release of cytokines
and chemokines.27 Another mechanism through which high
glucose increases the complications associatedwith diabetes is
production of reactive oxygen species (ROS). These ROS
suppress insulin production by inhibiting the transcription
factors of insulin in β-cells of the pancreas. ROS
cause endothelial dysfunction and induce synthesis of chemo-
kines such as MCP-1, ICAM 1, and IL-1. This further
upregulates the ROS production, leading to diabetes induced
atherosclerosis.28,29 Therefore, when serum glucose is con-
trolled, even in the context of obesity, there could be a down-
play of stresswhich in turn decreases the previouslymentioned
heightened release of cytokines and chemokines.
A few studies investigated the relation between obesity
and inflammation among patients with diabetes according to
their glycemic control. Mohan et al conducted a study on
Asian Indian patients with diabetes, and demonstrated higher
CRP levels among participants with increased HbA1c and
Table 2 Relation Between BMI And Abdominal Fat And Inflammatory Biomarkers In Patients With Type-2 Diabetes With Good
Glycemic Control (<7% HbA1C)a
CRP (mg/L) P-value IL-6 (pg/L) P-valueb
Mean ± SE Mean ± SE
Body mass indexc 0.269 0.666
Normal 3.73±1.22e 5.94±2.55e
Overweight 4.54±0.66e 2.12±0.25e
Obesity I 10.19±3.68e 3.96±1.02e
Obesity II 10.09±1.85e 4.32±1.43e
Obesity III 6.56±2.77e 6.35±2.55e
Abdominal fat %d 0.023 0.002
Low 3.92 ± 0.86e 4.90± 2.26ef
Average 5.53 ± 0.54e 2.68± 0.28e
High 14.20 ± 1.24f 6.40± 2.08f
Notes: an=67. Means sharing different. bP-values for F-statistic in multivariate-adjusted analysis of variance. Analysis was adjusted for age, gender, use of lipid-lowering
drugs, and diabetes duration. cNormal weight, BMI: 18.6 to 24.9 kg/m2; overweight: BMI: 25 to 29.9 kg/m2; obese grade I: BMI: 30 to 34.9 kg/m2; obese grade II: BMI:
35 to 39.9 kg/m2; and obese grade III: BMI: ≥40 kg/m2. dAbdominal fat % cut-off points: low (<13.5% for men, <29.4% for women); average (13.5% - <29% for men,
29.4% - <54.6% for women) and high: (≥29% for men, ≥54.6% for women).23 e,f,gMeans in the same column sharing different letters superscripts are significantly
different (P< 0.05).
Table 3 Relation Between BMI And Abdominal Fat And Biomarkers Of Inflammation In Patients With Type-2 Diabetes With Poor
Glycemic Control (≥7% HbA1C)a
CRP (mg/L) IL-6 (pg/L) P-valueb
Mean ± SEM
Body mass indexc 0.02 0.047
Normal 5.42±2.08e 4.06±1.82e
Overweight 6.79±1.18e 3.38±0.62e
Obesity I 7.80±0.97e 3.89±0.34e
Obesity II 11.17±1.16f 4.41±0.44ef
Obesity III 16.66±3.78g 6.10±0.93f
Abdominal fat %d 0.014 0.049
Low 8.82±4.25e 3.30±2.14e
Average 8.72±0.71e 4.24±0.31f
High 12.47±2.67f 4.42±0.60f
Notes: an=137. bP-values for F-statistic in multivariate-adjusted analysis of variance. Analysis was adjusted for age, gender, use of lipid-lowering drugs, and
diabetes duration. cNormal weight, BMI: 18.6 to 24.9 kg/m2; overweight: BMI: 25 to 29.9 kg/m2; obese grade I: BMI: 30 to 34.9 kg/m2; obese grade II: BMI: 35 to
39.9 kg/m2; and obese grade III: BMI: ≥40 kg/m2. dAbdominal fat % cut-off points: low (<13.5% for men, <29.4% for women), average (13.5% - <29% for men, 29.4%
- <54.6% for women), and high: (≥29% for men, ≥54.6% for women).23 e,f,gMeans in the same column sharing different letters superscripts are significantly different
(P< 0.05).
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tertiles of body fat.30 Zaciragic et al reported a direct relation
between serum CRP concentrations and BMI in T2D.31 The
same relationship was documented by Rawson et al. Other
obesity markers such as total fat percentage were also inves-
tigated in the literature in relation to inflammation among
patients with diabetes.32 The findings of our study are in line
with previously published work that showed an association
between circulatory markers of chronic inflammation (CRP,
IL-6) and body fat percentage.33–36 Other studies failed to
find an association between inflammatory response and obe-
sity among patients with diabetes, however.37 Investigators
interpret this controversy by the nonlinearity that may exist
between the cytokine levels and BMI of diabetic patients.
The scenario was different when examining abdominal fat
percentage. Regardless of the glycemic control of the patients,
abdominal fat percentage was associated with an increased
level of serum inflammatory biomarkers (CRP, IL-6). These
results were supported by findings from numerous studies that
depicted a positive correlation between CRP and abdominal
body fat.31,33,36 Rexrode et al and Park et al also reported a
very clear positive trend concerning CRP levels.38,39 A study
was conducted on elderly type 2 diabetic patients by Pedersen
et al in 2003.40 They found that high circulatory inflammatory
cytokines (IL-6 and TNF-α) were associated with increased
abdominal fat mass in patients with good and poor glycemic
control. The exact explanation of the relation between abdom-
inal fat and inflammatory response is not yet fully understood.
In vivo and in vitro studies detected amplified IL-6 production
by subcutaneous adipose cells with defects in insulin action.41
The distinctive role of intraperitoneal adipocytes as an active
gland results in the secretion of several hormones and several
adipocytokines.42 Once these cytokines are secreted by adipo-
cytes, this results in a boost in the CRP production via
hepatocytes.25,26
It is worthmentioning that although absolute HbA1c levels
were used as indicators of glycemic control, glucose variabil-
ity was not measured in this study. Hoffman et al reported on
17 adolescents with type 1 diabetes, stating that increased
glucose variability is associated with increased inflammation
in this group,43 suggesting that pathogenesis in type-1 diabetes
is different from T2D. It would be interesting to determine
whether patients in the non-controlled glycemia group had
increased instances of intermittent hyperglycemia or whether
it was sustained hyperglycemia. Animal studies have sug-
gested that intermittent hyperglycemia has a more marked
effect than sustained hyperglycemia in inducing oxidative
stress and increasing inflammation;44 however, studies in
human adults have been less conclusive. Many studies in
human adults have found no association between glucose
variability and consequences of inflammation, such as micro-
vascular or macrovascular complications, arterial stiffness,
and carotid intimal thickness.43 On the other hand, other
studies stated that fluctuations in glucose, especially during
post prandial periods, heightened the triggering effect on oxi-
dative stress compared to sustained hyperglycemia.45
Themajor strength of this study is the stringent procedure
we used for the selection of the participants to rule out any
acute response to inflammation. Due to the cross-sectional
nature of the study, results should not be viewed in terms of
cause and effect relationship. Due to the small sample size in
this study, results may not be applicable to the population at
large in Jordan. For the same reason, we were unable to
determine the relationship between body composition and
inflammation using various hyperglycemic levels. Future
studies should use more accurate body composition measure-
ment methods such as DEXA rather than bioelectrical impe-
dance methods that were used in this study.
In conclusion, the findings of the current study indicate
that abdominal fat is related to increased inflammation
regardless of glycemic control in Jordanian sample.
General obesity is associated with systemic inflammation
only among patients with poor glycemic control. Patients
should maintain HbA1C concentrations below 7% to
reduce the glucose induced inflammatory markers, as this
has been linked to complications associated with diabetes.
Longitudinal studies are needed to decipher the complex
relationship between body composition and inflammation
and its overall impact on progression of diabetes.
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